Controlled-release CNP agonists with reduced side-effects

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 11389511
APP PUB NO 20190328841A1
SERIAL NO

16067070

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates a pharmaceutical composition comprising a controlled-release CNP agonist which reduces CNP agonist-associated side-effects, the use of such controlled-release CNP agonist and to methods of treatment.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • ASCENDIS PHARMA GROWTH DISORDERS A/S

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Cleemann, Felix Mainz, DE 38 248
Hersel, Ulrich Heidelberg, DE 68 824
Rasmussen, Caroline Elisabeth Virum, DK 10 51
Rau, Harald Dossenheim, DE 107 1491
Sprogøe, Kennett Holte, DK 52 241

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Jan 19, 2026
7.5 Year Payment $3600.00 $1800.00 $900.00 Jan 19, 2030
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 19, 2034
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00